Literature DB >> 27960205

The Role of Streptococcus pneumoniae in Community-Acquired Pneumonia.

Charles Feldman1, Ronald Anderson2.   

Abstract

Streptococcus pneumoniae (the pneumococcus) remains one of the most common causes of bacterial community-acquired pneumonia (CAP), encompassing infections mild enough to be treated on an outpatient basis, as well as those requiring hospital care, or even intensive care unit admission. This microorganism is associated with a significant burden of disease, causing substantial morbidity and mortality worldwide, and generating considerable health-care costs. The reason that pneumococcal CAP remains such a common cause of disease relates to the presence of several risk factors for this infection in patients throughout the world. Such risk factors include extremes of age, lifestyle factors, including smoking and alcohol abuse, and various underlying comorbid conditions, including congenital and acquired immunodeficiencies. This article will review various aspects of pneumococcal CAP, including the burden of pneumococcal disease, risk factors for pneumococcal infection, the occurrence of cardiovascular events in patients with pneumococcal CAP, the apparently pivotal role of pneumolysin, a major virulence factor of the pneumococcus, in the pathogenesis of severe infection and associated cardiac dysfunction, empiric antibiotic treatment for pneumococcal CAP, as well as adjunctive therapies, specifically those which target pneumolysin, and, finally, the mortality of such infections. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2016        PMID: 27960205     DOI: 10.1055/s-0036-1592074

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  8 in total

Review 1.  Host-Pathogen Interactions in Gram-Positive Bacterial Pneumonia.

Authors:  Jennifer A Grousd; Helen E Rich; John F Alcorn
Journal:  Clin Microbiol Rev       Date:  2019-05-29       Impact factor: 26.132

2.  Pneumolysin induces platelet destruction, not platelet activation, which can be prevented by immunoglobulin preparations in vitro.

Authors:  Kristin Jahn; Stefan Handtke; Raghavendra Palankar; Sabrina Weißmüller; Geraldine Nouailles; Thomas P Kohler; Jan Wesche; Manfred Rohde; Corina Heinz; Axel F Aschenbrenner; Martina Wolff; Jörg Schüttrumpf; Martin Witzenrath; Sven Hammerschmidt; Andreas Greinacher
Journal:  Blood Adv       Date:  2020-12-22

3.  Interleukin 17 Receptor E (IL-17RE) and IL-17C Mediate the Recruitment of Neutrophils during Acute Streptococcus pneumoniae Pneumonia.

Authors:  Patrick Steck; Felix Ritzmann; Anja Honecker; Giovanna Vella; Christian Herr; Rosmarie Gaupp; Markus Bischoff; Timotheus Speer; Thomas Tschernig; Robert Bals; Christoph Beisswenger
Journal:  Infect Immun       Date:  2019-10-18       Impact factor: 3.441

Review 4.  Epidemiology, virulence factors and management of the pneumococcus.

Authors:  Charles Feldman; Ronald Anderson
Journal:  F1000Res       Date:  2016-09-14

5.  Synergistic Antimicrobial Effects of Cefabronchin®.

Authors:  Isabel Stephany-Brassesco; Stefan Bereswill; Markus M Heimesaat; Matthias F Melzig
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2019-06-27

6.  Pneumococcal superinfection in COVID-19 patients: A series of 5 cases.

Authors:  David Cucchiari; Juan M Pericàs; Josep Riera; Roberto Gumucio; Emmanuel Coloma Md; David Nicolás
Journal:  Med Clin (Engl Ed)       Date:  2020-12-14

7.  In vitro activity of lactone ketolide nafithromycin (WCK 4873) against Streptococcus pneumoniae isolates enriched with macrolide-resistance phenotype collected from mainland China.

Authors:  Menglan Zhou; Lijuan Wu; Wei Kang; Yanbing Li; Ge Zhang; Jingjia Zhang; Simeng Duan; Jin Li; Tong Wang; Yingchun Xu; Yihai Gu
Journal:  JAC Antimicrob Resist       Date:  2022-10-10

8.  Streptococcus pneumoniae binds to host GAPDH on dying lung epithelial cells worsening secondary infection following influenza.

Authors:  Sang-Sang Park; Norberto Gonzalez-Juarbe; Ashleigh N Riegler; Hansol Im; Yvette Hale; Maryann P Platt; Christina Croney; David E Briles; Carlos J Orihuela
Journal:  Cell Rep       Date:  2021-06-15       Impact factor: 9.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.